Raj Kasthuri, MD
Hematology · Chapel Hill, NCNPI 1861580441
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (39.4%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Pharmacosmos Therapeutics Inc. accounts for 85.7% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2023 at $24,850 and has fallen 80.6% since, to $4,832 in 2025.
Across 28 payments — averaging $1830.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pharmacosmos Therapeutics Inc.$44K
- HEMA Biologics, LLC$6K
- Alnylam Pharmaceuticals Inc.$1K
Across 117 payments — averaging $1212.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sobi, Inc$142K
What the payments were for
- Consulting fees$10,50020%
- Speaking & faculty fees$20,17439%
- Travel & lodging$19,87439%
- Food & beverage$7121%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pharmacosmos Therapeutics Inc. | 19 | $43,949 |
| HEMA Biologics, LLC | 2 | $6,000 |
| Alnylam Pharmaceuticals Inc. | 7 | $1,312 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Monoferric$43,800
- SevenFact$6,000
How this compares
$51,261 in reported general payments places this provider in the 70th percentile of 65 hematology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 67 | $50,139 |
| XareltoRivaroxaban | 39 | $36,218 |
| Tranexamic Acid | 103 | $21,369 |
| Fondaparinux Sodium | 12 | $14,262 |
Paid to pharmacies, not to this prescriber.
Other hematology in Chapel Hill
- Patrick EllsworthChapel Hill$22K
- Anson SnowChapel Hill$3K
- George FedoriwChapel Hill$788
- Daniel RichardsonChapel Hill$109
- Ryan JacobsCharlotte$1.5M
- Alan Zausner SkarbnikCharlotte$1.1M
- Mohamed MohamedGreensboro$841K
- Raymond ThertulienCharlotte$561K
- Ruben MesaCharlotte$384K
- Michael GrunwaldCharlotte$344K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.